GBS (Group B Streptococcus) is a type of bacterial infection that causes life-threatening diseases in newborns and also affects pregnant women and adults with other health conditions. The GBS diagnosis market involves the various techniques and tests used to detect the presence of GBS bacteria in expectant mothers during pregnancy. GBS diagnosis products include rapid diagnostic tests, culture media and reagents, and PCR assays which help identify GBS carriers and provide prophylaxis and treatment to reduce the risk of transmission from mother to newborn.
The group B streptococcus (GBS) diagnosis market is estimated to be valued at USD 1.58 billion in 2024 and is expected to reach USD 2.28 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Key Takeaways
Key players operating in the GBS diagnosis market are Thermo Fisher Scientific, Novamed, Beckman Coulter, BioMerieux, and Cepheid. These major players are focusing on new product launches and expansion strategies to strengthen their market position.
The growing awareness initiatives by healthcare organizations and governments regarding GBS screening during pregnancy present lucrative growth opportunities. Diagnostic guidelines recommending universal prenatal screening of all pregnant women have boosted Group B Streptococcus (GBS) Diagnosis Market revenues.
The rising cases of early-onset GBS disease worldwide has prompted diagnostic companies to expand their geographical presence. Regional partners and distribution networks help companies cater to the growing diagnostics demand globally, especially in developing nations.
Market Drivers
A key driver for the GBS diagnosis market is the increasing awareness among expecting mothers and healthcare providers regarding the importance of GBS detection. Universal prenatal screening protocols and recommendations by ACOG and CDC have boosted early diagnosis. This has translated to greater demand for rapid diagnostic tests, culture media, and molecular assays for optimal screening and management of GBS colonization during pregnancy.
PEST Analysis
Political: Health policies, regulations, programs and investments in healthcare research that determine availability of diagnostic services.
Economic: Factors like increasing healthcare spending, demand for affordable diagnostics and economic growth influence adoption and utilization of GBS diagnosis tests.
Social: Growing awareness about maternal and newborn health, risks associated with GBS infection and need for early diagnosis drive testing rates.
Technological: Advancements in molecular diagnostic techniques, automation and point-of-care testing enable rapid, accurate and early GBS detection. Digital technologies also facilitate better patient education and management.
Market Concentration by Geography
North America and Europe currently account for the largest share of the global GBS diagnosis market in terms of value due to established healthcare systems, advanced technologies, growing awareness and early adoption of diagnostic services. Major countries include the United States, Germany, the United Kingdom and France.
Fastest Growing Regional Market
The Asia Pacific region, especially China and India, is expected to witness the fastest growth over the forecast period. This can be attributed to rising incomes, improving access to healthcare, increasing government focus on maternal and child health through initiatives such as universal health coverage and growing penetration of advanced diagnostic technologies in healthcare facilities.
Get This Report in Japanese Language: グループB連鎖球菌診断市場
Get This Report in Korean Language: 그룹 B 연쇄상구균 진단 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
